Pfizer to acquire ReViral and its respiratory syncytial virus therapeutic candidates
Pfizer has announced its acquisition of ReViral to advance disease…
Pfizer has announced its acquisition of ReViral to advance disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus infections and prevent illness through vaccination.